Jordi Barquinero Mañez I am an MD, specialized in Internal Medicine, and senior researcher at the Vall d'Hebron Research Institute (VHIR). Doctor from the UAB with Extraordinary Award. I received post-doctoral training at the Fred Hutchinson Cancer Research Center (Seattle). I am currently leading the Gene and Cell Therapy group at the VHIR. My interest has focused on understanding disease mechanisms and finding effective therapies for orphan diseases. In our laboratory we have worked on gene therapy research projects for several rare diseases, mainly of genetic origin. Institutions of which they are part Head of group Gene and Cell Therapy Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Jordi Barquinero Mañez LinkedIn Twitter Orcid Institutions of which they are part Head of group Gene and Cell Therapy Vall Hebron Institut de Recerca I am an MD, specialized in Internal Medicine, and senior researcher at the Vall d'Hebron Research Institute (VHIR). Doctor from the UAB with Extraordinary Award. I received post-doctoral training at the Fred Hutchinson Cancer Research Center (Seattle). I am currently leading the Gene and Cell Therapy group at the VHIR. My interest has focused on understanding disease mechanisms and finding effective therapies for orphan diseases. In our laboratory we have worked on gene therapy research projects for several rare diseases, mainly of genetic origin.
I am an MD specialized in Internal Medicine (Vall d'Hebron University Hospital). I worked at the Intensive Care Unit (HUVH) and the Emergency Department of the Hospital de l'Esperança. I did pre-doctoral studies on autoimmunity at the University of Louisville (Dr. N. Harris) and got my PhD at the Autonomous University of Barcelona with Extraordinary Award, with a work that contributed to the description of a new disease, the primary antiphospholipid syndrome. I was a postdoc at the Fred Hutchinson Cancer Research Center (Dr. R. Storb, Seattle), where I was trained in hematopoietic stem cell gene therapy. I am currently group leader of the gene and cell therapy group (VHIR), where we investigate new therapeutic strategies for rare genetic diseases, mostly in collaboration with other groups on campus and from other national and international institutions. We have participated in research projects using models of multiple sclerosis, hemophilia, MNGIE, in a clinical trial for Fanconi anemia type A (coordinated by Drs. J. Bueren and P. Río, at the CIEMAT (Madrid)), and more recently, in a novel gene therapy approach for muscular dystrophy due to merosin deficiency, in collaboration with the Pediatric Neurology group (Drs. F. Munell and D. Gómez). Our group is part of the national network TERAV (RICORS). I have participated in European projects (INHERINET, CONSERT), including one as coordinator (HEMO-IPS, e-Rare-2), in which we experimentally demonstrated the mutagenic mechanism of the "Royal disease", the form of hemophilia B that affected several European royal families in the 19th and 20th centuries. I participate as a teacher in different master's degrees and I am a member of the American and European Gene and Cell Therapy Societies, and was one of the founding members of the Spanish Society of Gene and Cell Therapy.
Projects Terapia génica para el tratamiento del MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy). Introducción del gen timidina fosforilasa en líneas celulares humanas y en un doble knock-out murino como modelos experimentales IP: Ramon Martí Seves Collaborators: Jordi Barquinero Mañez, Marc Pellicer Sarasa Funding agency: Instituto de Salud Carlos III Funding: 180895 Reference: PI060735 Duration: 01/01/2007 - 30/12/2009 Inducció de tolerància mitjançant el quimerisme molecular: la encefalomielitis autoimmune experimental com a model. Mecanismes cel·lulars i optimització IP: Jordi Barquinero Mañez Collaborators: - Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 955 Reference: 2006FI 00664 Duration: 01/01/2006 - 31/12/2009 Quimerismo molecular como inductor de tolerancia en la encefalomielitis autoinmune experimental: mecanismos y optimización IP: Jordi Barquinero Mañez Collaborators: Francisco Vidal Pérez, Herena Eixarch Ahufinger, Carmen Espejo Ruiz Funding agency: Instituto de Salud Carlos III Funding: 177310 Reference: PI051441 Duration: 01/01/2006 - 31/12/2009 Concerted safety & efficiency evaluation of retroviral transgenesis in gene therapy of inherited diseases. Acronym: CONCERT FP6, Integrated Project Contract No 005242 LSHB-CT-2004-005242 IP: Jordi Barquinero Mañez Collaborators: Herena Eixarch Ahufinger Funding agency: EUROPEAN COMMISSION Funding: 307500 Reference: FP6-CONSERT-5242 Duration: 01/01/2005 - 01/01/2009 Pagination First page « Previous page ‹ … Page 3 Page 4 Current page 5 Page 6 Page 7 Next page › Last page »
